May 2, 2019   SOURCE: PR NewsWire

Global Erectile Dysfunction (ED) Drugs Market to 2023 with Bayer, Eli Lilly and Co, Pfizer, Teva Pharma, & Vivus Dominating

DUBLIN, May 2, 2019 /PRNewswire/ -- The "Global Erectile Dysfunction (ED) Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The erectile dysfunction (ED) drugs market will register a CAGR of over 4% by 2023.

The high prevalence of conditions resulting in ED is one of the key factors expected to trigger the market's growth in the forthcoming years. Various health conditions including diabetes, hypertension, obesity, depression, stress, and excessive alcohol consumption are resulting in the rising incidences of ED among elderly as well as young people. As these conditions directly alter the normal physiological levels of hormones, enzymes, and other factors, problems including penile erection have surged considerably in the recent years. These issues will further lead the erectile dysfunction drugs market to register a significant growth in the forthcoming years.

Market Overview

Rising demand for ED drugs

One of the growth drivers of the global erectile dysfunction (ED) drugs market is the rising demand for ED drugs. The rising cyber pornography and the increasing number of advertisements for the treatment of ED are expected to propel the growth of the global erectile dysfunction (ED) drugs market during the forecast period.

Side effects of available drugs

One of the challenges in the growth of the global erectile dysfunction (ED) drugs market is the side effects of available drugs. The alterations in the blood flow, which are caused by ED drugs, result in side-effects such as headache, vision changes, and dizziness, which will hinder the growth of the market.

Competitive Landscape

The market appears to be moderately concentrated with the presence of a few market players. Many vendors in the market are focusing on expanding research for the development of novel therapies such as stem cells for the treatment of ED. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

    --  Market ecosystem
    --  Market characteristics
    --  Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

    --  Market definition
    --  Market sizing 2018
    --  Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

    --  Bargaining power of buyers
    --  Bargaining power of suppliers
    --  Threat of new entrants
    --  Threat of substitutes
    --  Threat of rivalry
    --  Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

    --  Market segmentation by product
    --  Comparison by product
    --  Oral drugs - Market size and forecast 2018-2023
    --  Topical drugs - Market size and forecast 2018-2023
    --  Others - Market size and forecast 2018-2023
    --  Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

    --  Geographic segmentation
    --  Geographic comparison
    --  North America - Market size and forecast 2018-2023
    --  Europe - Market size and forecast 2018-2023
    --  Asia - Market size and forecast 2018-2023
    --  ROW - Market size and forecast 2018-2023
    --  Key leading countries
    --  Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

    --  Market drivers
    --  Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

    --  Overview
    --  Landscape disruption

PART 14: VENDOR ANALYSIS

    --  Vendors covered
    --  Vendor classification
    --  Market positioning of vendors
    --  Bayer AG
    --  Eli Lilly and Company
    --  Pfizer Inc.
    --  Teva Pharmaceutical Industries Ltd.
    --  VIVUS Inc.

PART 15: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/b5eu3n

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-erectile-dysfunction-ed-drugs-market-to-2023-with-bayer-eli-lilly-and-co-pfizer-teva-pharma--vivus-dominating-300841906.html

SOURCE Research and Markets